Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03778554 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction

Study acronym: DANBLOCK
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint revised
    • Secondary endpoints revised (23)
    • Study description expanded, about 25 words
    v9
  2. Study completion date: Apr 1, 2025 to Dec 10, 2035v8
  3. Study description expanded, about 15 wordsv7
  4. Trial status: Recruiting to Active, Not Recruiting
    • Primary and study completion dates: Dec 10, 2024 to Apr 1, 2025
    • Secondary endpoints: details revised at 16 of 23 entries
    • Site details revised
    v6
  5. Primary completion date: Dec 31, 2023 to Dec 10, 2024v5 Show 5 more changesShow less
    • Primary endpoint revised
    • Enrollment target: 3570 to 2760
    • Study completion date: Jun 30, 2024 to Dec 10, 2024
    • Secondary endpoints: 20 to 23
    • Study description expanded, about 505 words
Show 3 earlier versionsHide 3 earlier versions
  1. Primary completion date: Dec 31, 2022 to Dec 31, 2023v4 Show 4 more changesShow less
    • Primary endpoint revised
    • Study completion date: Dec 31, 2023 to Jun 30, 2024
    • Secondary endpoints: details revised at 12 of 20 entries
    • Study description expanded, about 33 words
  2. Primary completion date: Dec 17, 2020 to Dec 31, 2022
    • Study completion date: Dec 17, 2022 to Dec 31, 2023
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Collaborators: 7 to 24
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To determine whether long-term treatment with oral betablocker therapy after myocardial infarction in patient with no heart failure reduces the composite outcome of recurrent MI, all-cause mortality, revascularisation with percutaneous coronary intervention or coronary artery bypass graft, ischemic stroke, incident heart failure, or malignant ventricular arrhythmia including resuscitated cardiac arrest of cardiac origin.
Trial Details
NCT Number NCT03778554
Lead Sponsor Bispebjerg Hospital
Collaborators: Amager Hospital, University Hospital Bispebjerg and Frederiksberg, Bornholm Hospital, Gentofte Hospital, Glostrup University Hospital, Copenhagen, Herlev Hospital, Hvidovre University Hospital, Nordsjaellands Hospital, Holbaek Hospital, Nykoebing Hospital, Naestved Hospital, Zealand University Hospital, Slagelse Hospital, Odense University Hospital, Svendborg Hospital, Sydvestjysk Sygehus, Hospital of Southern Jutland, Sygehus Lillebaelt (Vejle and Kolding), Aarhus University Hospital, Hospitalsenheden Midt, Hospitalsenheden Vest, Regionshospitalet Horsens, Silkeborg Sygehus, Aalborg University Hospital
Conditions
(from sponsor)		 Acute Myocardial Infarction, Non-ST Elevation Myocardial Infarction (nSTEMI), ST Elevation Myocardial Infarction
Related terms Non-ST Elevated Myocardial Infarction, ST Elevation Myocardial Infarction
Enrollment 2,760 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov